Traction bronchiectasis is a serious radiological finding, not because the stretched airways themselves are dangerous, but because they serve as reliable proof that the surrounding lung tissue has already been scarred by fibrosis. Research consistently links the extent and progression of traction bronchiectasis to worse lung function, poorer quality of life, and higher mortality risk. What makes this finding particularly worth understanding is a shift in how clinicians interpret it: once dismissed as a harmless side effect visible on CT scans, it is now recognized as one of the most important markers for gauging how severe fibrotic lung disease has become and how it is likely to progress.
What Traction Bronchiectasis Actually Is
Normal bronchiectasis refers to permanently widened airways, usually caused by infection or chronic inflammation that damages the airway walls directly. Traction bronchiectasis is a different animal. It happens when fibrotic scar tissue in the lung retracts and pulls on nearby airways, stretching them open from the outside. The airways themselves are not the problem; they are being distorted by the stiff, scarred tissue surrounding them.1PubMed Central. Clinical implications of traction bronchiectasis in IPF and fibrotic RA-ILD – a retrospective single-center cohort study On a CT scan, these stretched airways have a characteristic look that radiologists can distinguish from infection-driven bronchiectasis, and their presence in the lung provides confident evidence that fibrosis has already taken hold.
This distinction matters because the treatment implications are completely different. Infectious bronchiectasis often involves antibiotics and airway clearance therapy. Traction bronchiectasis, on the other hand, cannot be treated by targeting the airways. The underlying fibrosis is the disease, and the widened airways are its signature.
Why Radiologists and Clinicians Pay Close Attention to It
For years, traction bronchiectasis was treated as a secondary observation on imaging reports, something that confirmed fibrosis was present but didn’t itself add much clinical value. That view has changed. Traction bronchiectasis and its smaller cousin, traction bronchiolectasis, are now considered among the most persistent and reliable indicators of how severe fibrotic lung disease is and how it is likely to behave over time.2PubMed Central. Spectrum of Pulmonary Fibrosis from Interstitial Lung Abnormality to Usual Interstitial Pneumonia
Part of why clinicians value this marker so highly is its consistency across diseases. Whether you are looking at idiopathic pulmonary fibrosis, fibrosis linked to rheumatoid arthritis, systemic sclerosis, or even radiation injury, the presence and extent of traction bronchiectasis tracks with the severity of fibrosis in a way that is measurable and reproducible on imaging. In a cohort study of 267 patients with idiopathic pulmonary fibrosis and 56 with rheumatoid arthritis-related lung disease, the severity of traction bronchiectasis correlated strongly with the overall extent of fibrosis.1PubMed Central. Clinical implications of traction bronchiectasis in IPF and fibrotic RA-ILD – a retrospective single-center cohort study
The Link to Mortality
This is the finding that elevated traction bronchiectasis from a radiological footnote to a genuine clinical concern: its severity and progression independently predict survival. In the same cohort study mentioned above, higher bronchiectasis severity scores were independently associated with death even after accounting for the overall extent of fibrosis. The hazard ratio was modest per individual point on the scoring scale but statistically significant, meaning that among patients with similar levels of total fibrosis, those with more severe airway distortion fared worse.1PubMed Central. Clinical implications of traction bronchiectasis in IPF and fibrotic RA-ILD – a retrospective single-center cohort study
A population-based study from the Reykjavik cohort reinforced this conclusion from a different angle. Rather than measuring severity at one point in time, it tracked whether traction bronchiectasis got worse over the years. Patients whose traction bronchiectasis progressed had roughly 70% higher all-cause mortality compared to those whose imaging stayed stable, after adjusting for age, sex, body mass, and smoking history.3PubMed Central. Progression of traction bronchiectasis/bronchiolectasis in interstitial lung abnormalities is associated with increased all-cause mortality
A large imaging study across multiple subtypes of fibrotic interstitial lung disease found that the extent of traction bronchiectasis on CT independently predicted transplant-free survival, alongside honeycombing, pulmonary artery size, and the presence of subpleural sparing. For every 10% increase in lung involvement by traction bronchiectasis, the risk of death or need for transplant rose by about 18%.4PubMed. CT Honeycombing and Traction Bronchiectasis Extent Independently Predict Survival across Fibrotic Interstitial Lung Disease Subtypes These are not enormous individual risk jumps, but in diseases that tend to progress incrementally over years, they translate into meaningfully different survival curves.
How It Affects Breathing and Quality of Life
Traction bronchiectasis does not just predict worse outcomes statistically; patients with more severe airway distortion tend to have measurably worse breathing capacity. Research in patients with idiopathic pulmonary fibrosis found that increasingly severe traction bronchiectasis was independently linked to lower gas transfer, reduced lung volume, and lower blood oxygen levels, even after accounting for the extent of fibrosis and emphysema present.5PubMed. Traction bronchiectasis in cryptogenic fibrosing alveolitis: associated computed tomographic features and physiological significance In other words, two patients with similar overall amounts of scarring can have meaningfully different breathing capacity depending on how much airway distortion is present.
Quality of life tracks with this, too. A large analysis from the COPDGene study showed that patients with more pronounced traction bronchiectasis on their CT scans reported progressively worse quality-of-life scores. The relationship was graded: the worst category of traction bronchiectasis was associated with dramatically poorer quality of life compared to the mildest category.6PubMed Central. Traction Bronchiectasis/Bronchiolectasis on CT Scans in Relationship to Clinical Outcomes and Mortality: The COPDGene Study
There is an interesting wrinkle, though. One study that specifically tracked the rate at which traction bronchiectasis worsened over time in individual patients found no significant correlation between the speed of airway widening and the rate of lung function decline.7European Respiratory Journal. Correlation of traction bronchiectasis with lung function decline in patients with interstitial lung diseases This was a small study and its findings haven’t overturned the larger body of evidence, but it does suggest the relationship between airway distortion and functional decline is not perfectly linear. The severity at any given time matters for prognosis; the short-term pace of change may be less informative. Researchers are still sorting this out.
Conditions That Cause Traction Bronchiectasis
Traction bronchiectasis is not a standalone disease. It appears as a feature of a range of conditions that produce lung fibrosis. Understanding which conditions cause it helps clarify why it shows up on your imaging and what it means for you specifically.
- Idiopathic pulmonary fibrosis (IPF): This is the most common and most studied context. IPF is a progressive fibrotic lung disease with no known cause, and traction bronchiectasis is one of its hallmark CT findings. In IPF, the fibrosis tends to be relentless, and the airway distortion typically worsens over time.
- Autoimmune-related lung disease: Rheumatoid arthritis, systemic sclerosis, and other connective tissue diseases can all produce lung fibrosis that generates traction bronchiectasis. In systemic sclerosis, imaging studies show that progression often involves increasing traction bronchiectasis alongside worsening reticulation and volume loss.8Arthritis & Rheumatology. Progression Patterns in Systemic Sclerosis – Associated Interstitial Lung Diseases Severe traction bronchiectasis can accompany a pattern of fibrotic nonspecific interstitial pneumonia that sometimes develops in these patients.9American Journal of Respiratory and Critical Care Medicine. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
- Radiation-induced lung injury: The late phase of radiation injury to the lung, which occurs months to years after chest radiation therapy, typically manifests as traction bronchiectasis along with volume loss and scarring.10PubMed. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis Cancer survivors who received thoracic radiation should be aware that this is a recognized long-term effect.
- Post-COVID lung injury: Some people who developed severe COVID-19 with acute respiratory distress syndrome showed traction bronchiectasis on follow-up imaging. Uniquely among this list, much of that airway distortion resolved over time in most patients.11PubMed Central. Reversible Bronchiectasis in COVID-19 Survivors With Acute Respiratory Distress Syndrome: Pseudobronchiectasis
The prognosis associated with traction bronchiectasis depends heavily on the underlying disease. In IPF, the fibrosis is typically progressive and the outlook is the most guarded. In autoimmune conditions, immunosuppressive treatment may slow or stabilize fibrosis in some patients. In radiation injury, the fibrosis is usually stable once established, though the affected lung tissue does not recover. In post-COVID cases, genuine reversal is possible.
When Traction Bronchiectasis Can Reverse
One of the most common questions people have after seeing “traction bronchiectasis” on a radiology report is whether it can go away. The traditional answer has been no: once fibrosis distorts the airways, the change is permanent. But COVID-19 provided an unexpected exception to that rule.
Researchers studying COVID survivors with severe acute respiratory distress syndrome found that many patients initially showed traction bronchiectasis on their follow-up CT scans, but the airway distortion was absorbed completely in most of them over time. In a few patients the bronchiectasis did not fully disappear, but the degree of airway widening was significantly reduced.11PubMed Central. Reversible Bronchiectasis in COVID-19 Survivors With Acute Respiratory Distress Syndrome: Pseudobronchiectasis This pattern earned the term “pseudobronchiectasis,” because the initial CT appearance mimicked established traction bronchiectasis but turned out to reflect temporary lung distortion rather than permanent scarring.
The takeaway is not that all traction bronchiectasis might be reversible. In the context of IPF, autoimmune-driven fibrosis, or chronic radiation injury, it almost certainly is not. But in acute inflammatory conditions where the fibrosis-like changes may represent edema and organizing inflammation rather than true architectural remodeling, what looks like traction bronchiectasis on an early CT scan sometimes resolves. If you have been told you have traction bronchiectasis after a severe acute illness, follow-up imaging over several months is worthwhile before concluding the changes are permanent.
How Imaging Is Getting Better at Measuring Severity
A persistent challenge in managing fibrotic lung disease has been measuring traction bronchiectasis consistently. Radiologists can see it, but grading how bad it is involves some subjectivity. Two radiologists looking at the same scan might score it differently, and subtle worsening between scans can be hard to catch by eye.
Recent work has applied deep learning algorithms to this problem with promising results. A study using a 3D deep learning model to automatically measure total airway volume on CT scans found that a 1% increase in airway volume relative to total lung volume was associated with a threefold increased likelihood of developing progressive disease, even after controlling for the total amount of fibrosis visible on the scan. In patients with IPF, this automated measurement predicted mortality independently of overall fibrosis extent and could identify patients at high risk of progression at 12 months.12European Respiratory Journal. Deep learning-based quantification of traction bronchiectasis severity for predicting outcome in idiopathic pulmonary fibrosis
This kind of automated quantification could make a real practical difference. If a computer can measure airway distortion precisely and reproducibly, clinicians could detect subtle worsening earlier, potentially triggering treatment changes or clinical trial enrollment sooner. It could also reduce the variability in how different hospitals and radiologists assess the same scans, making it easier to compare patients across centers and track disease over time.
Traction Bronchiectasis in Children
Fibrotic lung disease is far less common in children than in adults, but it does occur, and traction bronchiectasis shows up in pediatric cases as well. A comprehensive analysis of children with interstitial lung disease found traction bronchiectasis in about one in five patients with signs of pulmonary fibrosis.13European Respiratory Journal. Understanding Pulmonary Fibrosis in Pediatric Interstitial Lung Disease: A Comprehensive Analysis The causes of childhood interstitial lung disease are quite different from the adult forms. Genetic conditions, surfactant dysfunction disorders, and developmental abnormalities all play a larger role. But the imaging finding of traction bronchiectasis has the same basic meaning: it reflects underlying fibrotic remodeling of the lung.
For parents who see this term on their child’s radiology report, it is worth knowing that the natural history of pediatric fibrotic lung disease varies enormously depending on the specific diagnosis. Some pediatric conditions stabilize or even improve as children grow, while others are progressive. The presence of traction bronchiectasis alone does not dictate the course; it needs to be interpreted in the context of the specific disease causing it.
What Treatment Looks Like
There is no treatment directed at traction bronchiectasis itself. The stretched airways are a consequence of the fibrosis around them, so treatment focuses on whatever is driving the fibrosis. In IPF, the two approved antifibrotic medications, pirfenidone and nintedanib, work by slowing the rate at which fibrosis progresses. They do not reverse existing scarring, and by extension they do not reverse existing traction bronchiectasis, but they may slow the pace at which it worsens. In autoimmune-related fibrotic lung disease, immunosuppressive therapies aimed at controlling the underlying autoimmune condition can sometimes stabilize the fibrosis.
Symptom management also matters. Patients with significant traction bronchiectasis often struggle with shortness of breath, reduced exercise tolerance, and chronic cough. Pulmonary rehabilitation, supplemental oxygen when needed, and careful management of any secondary infections in the damaged airways all form part of the care plan. In advanced cases, lung transplantation may be considered.
The practical implication for patients is that the finding of traction bronchiectasis on imaging should prompt a thorough evaluation of the underlying cause, because the treatment path depends entirely on what is producing the fibrosis. If the cause has not yet been identified, that workup becomes the immediate priority. If you are already being treated for a known fibrotic lung disease and new or worsening traction bronchiectasis appears on follow-up imaging, that is a signal to discuss whether the current treatment is doing enough to control disease progression.
Why This Finding Is Easily Misunderstood
A common source of confusion is that “bronchiectasis” and “traction bronchiectasis” sound like the same thing, and patients who look up bronchiectasis online land on information about the infection-driven form. The treatment advice for classic bronchiectasis, which includes airway clearance devices, nebulized medications, and long-term antibiotic strategies, largely does not apply to traction bronchiectasis. Conflating the two can lead to anxiety about the wrong things and pursuit of treatments that miss the point.
Another misconception is that traction bronchiectasis means the lungs are “collapsing.” What is actually happening is closer to the opposite: scar tissue is pulling airways open, making them wider than they should be. The lung tissue around those airways is stiff and shrunken, which reduces the lung’s ability to exchange gas, but the airways themselves are not blocked or closed. The mechanical distortion makes the lung less efficient, not less inflated.
Perhaps the most consequential misunderstanding is assuming that traction bronchiectasis is just a cosmetic finding on the scan, something radiologists report because they can see it but that does not change anything clinically. The evidence reviewed throughout this article makes clear that its presence, its extent, and its progression all carry real prognostic weight. Dismissing it as incidental can mean missing an opportunity to act earlier in the course of a progressive disease.